Johnson & Johnson COVID-19 Vaccine Produces Strong Immune Response In Early Trial

A single dose of Johnson & Johnson’s experimental COVID-19 vaccine produced a strong immune response against the novel coronavirus in an early-to-mid stage clinical trial, according to interim results published on Friday. The vaccine, called Ad26.COV2.S, was equally well-tolerated at two different doses, the results showed. A single shot, versus a rival two-dose approach being [R